Atara Biotherapeutics, Inc. (ATRA:NASDAQ) closed at $7.70 on November 13, 2026, down 2.90% on the day. The stock trades 59.8% below its 52-week high of $19.15 and 96.4% above its 52-week low of $3.92. Over the past year, it lost 44.0%. Atara Biotherapeutics, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 13, 2025, ATRA closed higher on 121 days (48%). Its best day was May 7, 2026 (+92.82%) and its worst was January 12, 2026 (-56.99%). The stock moved 10% or more in a single session 18 times. It opened at least 5% above the previous day's high 3 times.
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Find more stocks like ATRA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.